Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Investor Presentation (August 2020)

35 slides from Dicerna Pharmaceuticals's investor presentation, Aug 13, 2020

  1. Slide 1: Corporate Overview: Maximizing the Impact of RNAi on Medicine

    Exhibit 99.1 Corporate Overview Maximizing the Impact of RNAi on Medicine August 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi

  3. Slide 3: Vision and Strategy

    VISION Maximize the impact of RNAi on medicine STRATEGY Develop and commercialize our core high-probability-of-success programs either alone or in collaboration with partners Broadly enable the use of our GalXC technology by collaborating with therapeutic area leaders on non-core opportunities 3

  4. Slide 4: The RNAi Modality Has Come of Age

    The RNAi Modality Has Come of Age Many Thousands of Patients Have Been Treated With RNAi Therapeutics Multiple candidates in Approved registration or Dicerna was founded in Products pivotal 2007 to specialize in RNAi development Multiple committed large pharmas Many of the committed pharmas have cho

  5. Slide 5: Dicerna Pipeline of Core and Collaborative Programs

    Dicerna Pipeline of Core and Collaborative Programs DISCOVERY/ CLINICAL PROOF-OF- REGISTRATION DICERNA’S CANDIDATE TARGET INDICATION PRECLINICAL RESEARCH CONCEPT TRIALS TRIALS PRODUCT RIGHTS Primary Hyperoxaluria Nedosiran 100% Types 1,2,3 Core RG6346 Hepatitis B Virus U.S. opt-in* Programs (DCR-HBV

  6. Slide 6: Dicerna Is Creating Best-In-Class Opportunities

    We Believe Dicerna Is Creating Best-In-Class Opportunities In Primary Hyperoxaluria Dicerna conducted fundamental disease research to develop the LDHA mechanism to generate the most effective treatment for PH1 and the first treatment for PH2 and PH3 In Hepatitis B Dicerna’s X-sparing approach drives

  7. Slide 7: Platform Expansion to Achieve Effective Extrahepatic Delivery

    Platform Expansion to Achieve Effective Extrahepatic Delivery Including Central and Peripheral Nervous Tissues and Other Extrahepatic Tissues GalNAc sugars to bind hepatocyte ASGPR Liver-targeted GalXC is the basis of our current best-in-class core pipeline programs and most of our collaboration pro

  8. Slide 8: Key Achievements and Multiple Upcoming Milestone Targets

    Key Achievements and Multiple Upcoming Milestone Targets ✓ Nedosiran: Positive first multidose results from PHYOX3 open-label clinical trial – Q1 2020 ✓ RG6346: Positive Phase 1 proof-of-concept data from all existing cohorts – Q3 2020 ✓ GalXC: Positive data presented for extending GalXC technology

  9. Slide 9: Nedosiran for the Treatment of Primary Hyperoxaluria

    Nedosiran for the Treatment of Primary Hyperoxaluria

  10. Slide 10: Primary Hyperoxaluria

    Primary Hyperoxaluria A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications Known Types of Primary Hyperoxaluria The three known types of PH all PH1 PH2 PH3 result in overproduction of oxalate, Genetic mutation Genetic mutation Genetic mutation AGXT GRHPR HOGA1

  11. Slide 11: Positive Interim Results: Nedosiran PHYOX3 Multidose Open-Label Trial

    Positive Interim Results: Nedosiran PHYOX3 Multidose Open-Label Trial Mean Value for All Participants (n=11) in Near-Normal Range Starting Day 60 • PHYOX3 ongoing, three-year, multidose, Mean 24-Hour Urinary Oxalate Values open-label extension study (n=11, minimum 5 doses) ‒ Participants are Phase 1

  12. Slide 12: PHYOX3 Interim Analysis: Normalization or Near-Normalization of Uox Levels

    PHYOX3 Interim Analysis: Normalization or Near-Normalization of Uox Levels in 100% of PH1 Patients at One or More Timepoints • 4 of the 11 participants have reached normal Uox concentrations at 3 consecutive visits and are eligible for weaning off disease management, including hyperhydration – 1 add

  13. Slide 13: PHYOX3 Interim Safety Data

    PHYOX3 Interim Safety Data 301 Study • Favorable risk/benefit profile in this Category n (%) study Total TEAEs 16 (94.1) TEAEs occurring in >=10% of participants in group (n, %) Injection site discomfort 6 (35.3) • AEs mostly related to SC injection Injection site pain 6 (35.3) Injection site erythe

  14. Slide 14: Nedosiran Target Profile: Only RNAi Candidate for All PH Types

    Nedosiran Target Profile: The Only RNAi Drug Candidate in Development for All PH Types High Unmet Medical Need Across All PH Types Can Be Addressed Expected US Prevalence* Education Patient & Diagnostic Caregiver Testing Support Nedosiran Availability Similar numbers for major EU markets Estimated P

  15. Slide 15: RG6346 for the Treatment of Hepatitis B Virus Infection

    RG6346 for the Treatment of Hepatitis B Virus (HBV) Infection

  16. Slide 16: Hepatitis B: A Severe, Global Unmet Medical Need

    Hepatitis B: A Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected • Causes more than 887,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Dicerna is collaborating with Roche to develop RG6346 and potentially other

  17. Slide 17: The Promise of RNAi for the Treatment of Chronic HBV

    The Promise of RNAi for the Treatment of Chronic HBV Organization of the HBV Genome Enables Effective RNAi Targeting of Multiple Viral Functions Overlapping mRNAs enable targeting multiple HBV genes with RNAi Dicerna’s RG6346 molecule targets the Conserved S Region Preclinical analysis shows this is

  18. Slide 18: RG6346's X-Sparing Approach Demonstrates Superior HBsAg Reduction

    RG6346’s X-Sparing Approach Demonstrates Superior HBsAg Reduction When Targeting Only the Conserved S Region HBsAg Levels in HBV Core Protein HDI-HBV Plasmid Mouse Model Vehicle • With no treatment, Core (cccDNA-dependent) protein is in nucleus and 100 cytoplasm of liver cells Vehicle control 10 S a

  19. Slide 19: RG6346 Phase 1: Three-Part Safety, Tolerability, PK/PD Study

    RG6346 Phase 1: Three-Part Safety, Tolerability, PK/PD Study in Healthy Volunteers and Participants With Chronic Hepatitis B Randomized 2:1 active vs placebo, single-ascending- Completed RG6346 dose cohorts: Group A dose study in adult healthy volunteers n=30 0.1, 1.5, 3.0, 6.0, 12.0 mg/kg Randomize

  20. Slide 20: RG6346 Showed Strong, Durable Reduction in HBsAg Levels

    RG6346 Showed Strong, Durable Reduction in HBsAg Levels at All Doses Validates Predicted Long Duration of Effect Group C Dosing Cohorts Conditional Follow-Up • Mean maximal HBsAg reduction was 1.88 ⱡ log10 IU/mL (3 mg/kg cohort) ‒ 6 mg/kg cohort ongoing (only 2 of 4 ⱡ participants had reached Day 11

  21. Slide 21: NUC-Naïve Patient With Beneficial Flare

    NUC-Naïve Patient With Beneficial Flare As Defined in Clinical Trial Protocol, Suggesting Enhanced Patient Immune Response Two Additional Group B NUC-Naïve Patients Had Similar Beneficial Responses Reductions in All Viral Markers Synthetic and Excretory Liver Function Preserved Coincides with Benefi

  22. Slide 22: RG6346 Appeared Safe and Generally Well Tolerated

    In Phase 1 Patients, RG6346 Appeared To Be Safe and Generally Well Tolerated as of the Interim Analysis No Dose Effect on Liver Function Tests Observed in Healthy Volunteers at Dosages ≤12 mg/kg • No serious adverse events (SAEs) associated with RG6346 observed as of June 25, 2020 in Groups B or C ‒

  23. Slide 23: RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response

    RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response • Phase 1 proof-of-concept study confirms X-sparing hypothesis and potential for best-in-class activity • Extended duration of effect: 1.5 mg/kg cohort with no reduction in silencing at Day 336 • Beneficial ALT flares consistent wi

  24. Slide 24: DCR-A1AT and ALN-AAT02 for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    DCR-A1AT and ALN-AAT02 for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

  25. Slide 25: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Most Disease Is Caused by a Single Missense Allele That Forms Aggregates in Hepatocytes • Alpha-1 antitrypsin (A1AT): predominantly 1-Antitrypsin Deficiency produced in liver and secreted into blood Z mutation Glu342→Lys342 • Pi*ZZ genotype of

  26. Slide 26: Sustained Duration of Activity in Mice and Non-Human Primates With DCR-A1AT

    Sustained Duration of Activity Seen in Mice and Non-Human Primates Dosed With DCR-A1AT Sustained, Dose-Dependent Knockdown of A1AT Protein in Both Mice and Monkeys Z-AAT Protein Knockdown in PiZ Mice A1AT Protein Knockdown in Monkeys BS 3.0 mg/ g 1 5 3.0 mg/ g 1 5 10.0 mg/ g 10.0 mg/ g 100 100 SEM S

  27. Slide 27: A1AT Clinical Development Program

    A1AT Clinical Development Program Seeking a Rapid Path to Approval With the Strongest Candidate • Dicerna and Alnylam are collaborating on their DCR-A1AT and ALN-AAT02 programs • Dicerna is responsible for clinical development through approval, and Alnylam has rights to ex-U.S. commercialization of

  28. Slide 28: GalXC Extrahepatic Platform

    oe GalXC® Extrahepatic Platform Dicerna

  29. Slide 29: Expanding RNAi Delivery to Other Tissues

    Expanding RNAi Delivery to Other Tissues Expect Future Pipeline and Collaborations to Include Delivery Beyond Liver Non -Human Primate Gene Silencing Four Weeks After a Single RNAi Dose 1 SEM 5 ± 0 1 2 5 a C S 1 F Central Nervous System 0 0 (i .c .m 7 . Single 45 mg i.c.m. Dose 5 ) 5 % Target mRNA0

  30. Slide 30: Corporate Collaborations

    Corporate Collaborations Dicerna

  31. Slide 31: Successfully Executing on High-Value Collaboration Strategy

    Successfully Executing on High-Value Collaboration Strategy Collaborations Have Delivered >$500M in Upfront Payments $175M upfront $75M total annuals $200M upfront $50M equity • 30+ potential $100M upfront • RG6346 and targets for liver- $100M equity multiple potential related CM diseases HBV-relate

  32. Slide 32: Summary

    Summary Dicerna”

  33. Slide 33: Key Achievements and Multiple Upcoming Milestone Targets

    Key Achievements and Multiple Upcoming Milestone Targets ✓ Nedosiran: Positive first multidose results from PHYOX3 open-label clinical trial – Q1 2020 ✓ RG6346: Positive Phase 1 proof-of-concept data from all existing cohorts – Q3 2020 ✓ GalXC: Positive data presented for extending GalXC technology

  34. Slide 34: Well Positioned for Near- and Long-Term Success

    Well Positioned for Near- and Long-Term Success Driving Growth with Diversified Pipelines and Expanding Technology Platforms • Core Pipeline: Current pipeline yields multiple major milestones over next year+ ‒ Nedosiran: A differentiated therapy for all PH types (PH1, PH2 and PH3) ‒ RG6346: Potentia

  35. Slide 35: Slide 35

Dicerna Pharmaceuticals — Investor Presentation (August 2020) on 6ix